Olema Pharmaceuticals, Inc.

Roche Holding AG

Shares of Olema Pharmaceuticals, a small-cap maker of cancer drugs, <a href="https://finance.yahoo.com/quote/OLMA/">soared</a>&nbsp;almost 200% last week, November 18-24. Investors were <a href="https://www.roche.com/media/releases/med-cor-2025-11-18">reacting</a>&nbsp;to positive news on clinical trials from Swiss pharma giant Roche. Olema is advancing a therapy with a similar mechanism of action, meaning Roche’s success has reduced the perceived risks of investing in Olema, Freedom Broker explains. Against this backdrop, at least two Wall Street analysts have <a href="https://finance.yahoo.com/quote/OLMA/">raised</a>&nbsp;their target price on Olema shares.

Oncology drugmaker Olema triples in a week after latest Roche data eases sector risks

Siemens Energy AG

Schneider Electric S.E.

Bitcoin collapsed below $90k amid investors' flight from risks, but then recovered some of the losses

"Signal to sell": global stocks fall amid investor fatigue and cache shortages

Novo Nordisk A/S

AstraZeneca PLC

European pharma giants have a chance to avoid prohibitive duties on branded drugs, says JPMorgan Chase

Pharma stocks in Europe reacted weakly to Trump's threats of new duties

Shares of Poseida Therapeutics, which develops cell and gene therapies for cancers and genetic diseases, skyrocketed nearly 230% on Tuesday, November 26. The surge came after the <a href="https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-inc-announces-agreement-be-acquired-roche?utm_source=in_materials">announcement</a> of its acquisition by pharmaceutical giant Roche, with the deal valuing Poseida at $1.5 billion — triple its highest market value in the last year.

Poseida Therapeutics, cell therapy maker, triples on Nasdaq after being acquired by Roche

On Monday, October 7, shares of the biotech company Scholar Rock soared close to 362% following the <a href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-apitegromab-meets-primary-endpoint-phase-3">announcement</a> that its lead candidate, apitegromab, a treatment for spinal muscular atrophy (SMA), had demonstrated clinically significant results in the final, phase III trial. Currently, there are only three approved drugs for this genetic disease, with the SMA market <a href="https://www.biospace.com/spinal-muscular-atrophy-market-size-to-reach-us-13-0-billion-by-2034-impelled-by-increased-popularity-of-gene-therapy#:~:text=The%20spinal%20muscular%20atrophy%20market,14.28%25%20during%202024%2D2034.">estimated</a> at $3 billion in 2023.